ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Mycophenolate mofetil"

  • 2017 American Transplant Congress

    Mycophenolic Acid Needs Ca2+ to Exert Its Anti-inflammatory Action via Shedding of Toll-Like Receptor4 and Tumor Necrosis Factor Receptor 1.

    J. Kim,1 W. Yang,1 C. Baek,1 N. Han,2 S.-K. Park.1

    1Division of Nephrology, Department of Internal Medicine, Asan Medical Center, Seoul, Republic of Korea; 2Asan Institute for Life Science, Seoul, Republic of Korea

    Background Mycophenolic acid (MPA) has been used for many years to prevent transplantation rejection. Recently, it has been investigated for its anti-inflammatory effects. MPA can…
  • 2017 American Transplant Congress

    Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.

    H. Ahmed, A. Roche-Recinos, C. Drachenberg, R. Ugarte, N. Costa, M. Mavanur, B. Thomas, A. Haririan.

    Department of Medicine, University of Maryland Medical Center, Baltimore, MD

    The optimal approach for IS reduction in renal transplant recipients with BKN is not well defined. A number of clinical and in vitro studies suggest…
  • 2017 American Transplant Congress

    Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.

    K. Soliman, A. Posadas Salas, D. Taber.

    Transplant, MUSC, Charleston, SC

    There is strong evidence that both tacrolimus (FK) and mycophenolate (MMF) have improved outcomes in kidney transplantation; yet, the impact of exposure of these immunosuppressants…
  • 2017 American Transplant Congress

    Impact of Intensive Dosing of Mycophenolate on Pancreas Allograft Survival.

    J. Fose,1 K. Rolling,1 N. Menninga,1 G. Leverson,2 M. Jorgenson,1 J. Odorico,2 R. Robert.2

    1Pharmacy, UW Health, Madison, WI; 2Transplant Surgery, UW Health, Madison, WI

    Purpose: The primary objective was to evaluate the effect of mycophenolate (MPA) dicharge (DC) dose on pancreas allograft (PTX) survival. Secondary endpoints included patient survival…
  • 2017 American Transplant Congress

    Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.

    Y. Watarai,1 S. Narumi,1 M. Okada,1 R. Kimura,1 K. Hatazoe,1 K. Futamura,1 T. Yamamoto,1 T. Hiramitsu,1 M. Tsujita,1 N. Goto,1 T. Kobayashi.2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; 2Kidney Transplant Surgery, Aichi Medical University, Nagakute, Aichi, Japan

    Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…
  • 2017 American Transplant Congress

    Tacrolimus and Mycophenolate Exposure and Subclinical Tubulo-Interstitial Inflammation in Low Immunological Risk Renal Transplants.

    I. Torres,1 A. Reisaeter,2 F. Moreso,1 A. Asberg,2 M. Perello,1 C. Dörje,2 J. Sellares,1 K. Midtved,2 H. Holdaas,2 D. Seron.1

    1Nephrology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; 2Transplant Medicine, Rikshospitalet Oslo University Hospital, Oslo, Norway

    The aim is to evaluate the relationship between maintenance immunosuppression, subclinical inflammation (i-score plus t-score) and interstitial fibrosis/tubular atrophy (IF/TA) (ci-score plus ct-score) in paired…
  • 2016 American Transplant Congress

    Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.

    C.-D. Kim, J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim.

    Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.

    Background: Mycophenolic acid (MPA) is a widely used immunosuppressant to prevent acute rejection in kidney transplant recipients (KTRs). However, clinical significance of MPA therapeutic drug…
  • 2016 American Transplant Congress

    Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.

    K. Patel,1 B. Stephany,2 J. Barnes,1 S. Bauer,1 M. Spinner.1

    1Department of Pharmacy, Cleveland Clinic, Cleveland, OH; 2Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.

    Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…
  • 2016 American Transplant Congress

    Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.

    A. El-Agroudy,1 A. Taher,2 A. Alaradi,2 B. Alhayki,2 S. Gareeb,2 E. Farid.2

    1Internal Medicine, College of Medicine, Arabian Gulf University, Manama, Bahrain; 2Nephrology, Salmaniya Medical Complex, Manama, Bahrain.

    Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…
  • 2016 American Transplant Congress

    Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.

    Y. Watarai,1 M. Okada,1 K. Futamura,1 T. Nagai,1 T. Yamamoto,1 M. Tsujita,1 T. Hiramitsu,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; 2Kidney Transplant Surgery, Aichi Medical University, Nagoya, Aichi, Japan.

    Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences